Open AccessIpilimumab and Its Toxicities: A Multidisciplinary Approach
Author(s) -
Fecher Leslie A.,
Agarwala Sanjiv S.,
Hodi F. Stephen,
Weber Jeffrey S.
Publication year - 2013
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0483
Subject(s) - ipilimumab , medicine , clinical trial , adverse effect , immunotherapy , intensive care medicine , oncology , nivolumab , randomized controlled trial , multidisciplinary approach , cancer , social science , sociology
The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor‐1 and programmed death receptor ligand‐1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune‐related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.